Europe Narcolepsy Market to Reach US$ 1,532.5 Mn at a CAGR of 9.7% in 2027

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Narcolepsy Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Narcolepsy Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Increase in the prevalence of sleep disorders
5.1.2 Growing awareness of narcolepsy symptoms

5.2 Market Opportunities

5.2.1 Growth in narcolepsy diagnostic services
5.2.2 Expansion in treatment options

5.3 Future Trends

5.3.1 Development of personalized treatment plans
5.3.2 Increase in adoption of cognitive-behavioral therapy

5.4 Impact of Drivers and Restraints

6. Europe Narcolepsy Market Regional Analysis

6.1 Europe Narcolepsy Market Overview

6.2 Europe Narcolepsy Market Revenue 2016-2027 (US$ Million)

6.3 Europe Narcolepsy Market Forecast Analysis

7. Europe Narcolepsy Market Analysis – by Type

7.1 Narcolepsy with Cataplexy

7.1.1 Overview
7.1.2 Narcolepsy with Cataplexy: Europe Narcolepsy Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Narcolepsy without Cataplexy

7.2.1 Overview
7.2.2 Narcolepsy without Cataplexy: Europe Narcolepsy Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Secondary Narcolepsy

7.3.1 Overview
7.3.2 Secondary Narcolepsy: Europe Narcolepsy Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Narcolepsy Market Analysis – by Product

8.1 Central Nervous System Stimulants

8.1.1 Overview
8.1.2 Central Nervous System Stimulants: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

8.2 Sodium Oxybate

8.2.1 Overview
8.2.2 Sodium Oxybate: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

8.3 Antidepressants

8.3.1 Overview
8.3.2 Antidepressants: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

9. Europe Narcolepsy Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Antidepressants: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview
9.2.2 Antidepressants: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10. Europe Narcolepsy Market – Europe Analysis

10.1 Europe

10.1.1 Europe Narcolepsy Market Breakdown, by Key Country, 2019 and 2027 (%)
10.1.1.1 Europe Narcolepsy Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1.1 UK: Europe Narcolepsy Market Breakdown, by Type
10.1.1.1.2 UK: Europe Narcolepsy Market Breakdown, by Product
10.1.1.1.3 UK: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.1.1.2 Germany: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.2.1 Germany: Europe Narcolepsy Market Breakdown, by Type
10.1.1.2.2 Germany: Europe Narcolepsy Market Breakdown, by Product
10.1.1.2.3 Germany: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.1.1.3 France: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.3.1 France: Europe Narcolepsy Market Breakdown, by Type
10.1.1.3.2 France: Europe Narcolepsy Market Breakdown, by Product
10.1.1.3.3 France: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.1.1.4 Russia: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.4.1 Russia: Europe Narcolepsy Market Breakdown, by Type
10.1.1.4.2 Russia: Europe Narcolepsy Market Breakdown, by Product
10.1.1.4.3 Russia: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.1.1.5 Italy: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.5.1 Italy: Europe Narcolepsy Market Breakdown, by Type
10.1.1.5.2 Italy: Europe Narcolepsy Market Breakdown, by Product
10.1.1.5.3 Italy: Europe Narcolepsy Market Breakdown, by Distribution Channel

10.1.1.6 Rest of Europe: Europe Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Narcolepsy Market Breakdown, by Type
10.1.1.6.2 Rest of Europe: Europe Narcolepsy Market Breakdown, by Product
10.1.1.6.3 Rest of Europe: Europe Narcolepsy Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Narcolepsy Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Teva Pharmaceutical Industries Ltd.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Jazz Pharmaceuticals plc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Arena Pharmaceuticals, Inc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Graymark Healthcare, Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Novartis AG

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Takeda Pharmaceutical Company Limited

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Mylan N.V.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 BIOPROJET

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Shionogi & Co., Ltd.

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Ligand Pharmaceuticals, Inc

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights